Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001.

As a result of emerging biological data suggesting that within the c-Jun N-terminal kinase (JNK) family, JNK1 and not JNK2 or JNK3 may be primarily responsible for fibrosis pathology, we sought to identify JNK inhibitors with an increased JNK1 bias relative to our previous clinical compound tanzisertib (CC-930). This manuscript reports the synthesis and structure-activity relationship (SAR) studies for a novel series of JNK inhibitors demonstrating an increased JNK1 bias. SAR optimization on a series of 2,4-dialkylamino-pyrimidine-5-carboxamides resulted in the identification of compounds possessing low nanomolar JNK inhibitory potency, overall kinome selectivity, and the ability to inhibit cellular phosphorylation of the direct JNK substrate c-Jun. Optimization of physicochemical properties in this series resulted in compounds that demonstrated excellent systemic exposure following oral dosing, enabling in vivo efficacy studies and the selection of a candidate for clinical development, CC-90001, which is currently in clinical trials (Phase II) in patients with idiopathic pulmonary fibrosis (NCT03142191).

[1]  J. Alcorn,et al.  Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates pulmonary fibrosis in two independent mouse models , 2020, PloS one.

[2]  W. Reid,et al.  Idiopathic Pulmonary Fibrosis: A review of disease, pharmacological and non-pharmacological strategies with a focus on symptoms, function, and health-related quality of life. , 2019, Journal of pain and symptom management.

[3]  J. Liou,et al.  Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. , 2017, Journal of medicinal chemistry.

[4]  Mahmoud S. Assaf,et al.  JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers , 2016, Clinical and Translational Medicine.

[5]  A. Reményi,et al.  JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships , 2016, Microbiology and Molecular Reviews.

[6]  Marcus Schmidt,et al.  JNK-dependent gene regulatory circuitry governs mesenchymal fate , 2015, The EMBO journal.

[7]  G. Godeau,et al.  Picrosirius Red Staining , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  Philip Chamberlain,et al.  Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. , 2012, Bioorganic & medicinal chemistry letters.

[9]  K. Iwaisako,et al.  c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. , 2009, Gastroenterology.

[10]  J. Alcorn,et al.  c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. , 2009, American journal of respiratory cell and molecular biology.

[11]  M. Czaja,et al.  Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance , 2009, Hepatology.

[12]  Zigang Dong,et al.  The functional contrariety of JNK , 2007, Molecular carcinogenesis.

[13]  R. D. du Bois,et al.  Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors , 2006, Molecular and Cellular Biology.

[14]  D. Bar-Sagi,et al.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. , 2000, Science.

[15]  A. DeFranco,et al.  Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. , 1996, Proceedings of the National Academy of Sciences of the United States of America.